Update: Due to increased supply of nirsevimab, the Centers for Disease Control and Prevention (CDC) recommends returning to the original guidance set forth by the CDC and ACIP for use of nirsevimab in young children. To read the full announcement please click here. Additional guidance for RSV-prevention, including recommendations for the maternal RSV-vaccine, is now available within the CDC’s immunization schedule.

Background

Respiratory syncytial virus (RSV) is a common cause of respiratory illness in children and is the most common cause of hospitalization in infants. On July 17th, 2023 the FDA approved nirsevimab (BeyfortusTM), a monoclonal antibody indicated for the prevention of severe RSV for infants and select high risk children. On August 3rd, The Advisory Committee on Immunization Practices (ACIP) unanimously recommended the addition of nirsevimab to the Centers for Disease Control and Prevention’s (CDC’s) child immunization schedule and Vaccines for Children (VFC) program. The CDC recommends one dose of nirsevimab for all infants younger than 8 months, born during or entering their first RSV season. Additionally, it is recommended for children 8 to 19 months old who are at increased risk for severe RSV disease during their 2nd RSV season. Partners For Kids will update this page when new information and resources become available.

Partners For Kids Communication

Here you will find Partners For Kids developed content around RSV prevention, including
newsletter updates and webinars.

• Newsletter Communication
• Webinar
• Webinar Slide Deck

For Healthcare Professionals

This section contains links to reputable sources of information for health care professionals to learn more about nirsevimab and RSV-prevention.

• Nirsevimab supply chain issues – updated 10/17/2023
• VFC operation guide nirsevimab addendum from CDC – updated 12/1/2023
• Information about maternal RSV vaccination from CDC – updated 12/1/2023
• Nirsevimab recommendations from ACIP and AAP (Redbook)
• Nirsevimab in Morbidity Mortality Weekly Report from CDC
• Nirsevimab package insert 
• Additional AAP resources
  • Nirsevimab FAQs
  • Nirsevimab ordering and product information 
  • Nirsevimab payment and coding 
  • Nirsevimab practice readiness checklist – updated 12/1/2023
  • Nirsevimab outpatient practice implementation guide – updated 12/1/2023

For Patients

These links are to patient facing websites and material that help to explain the importance of RSV-prevention and the recommendations for using nirsevimab.

• CDC Immunization Information Sheet (IIS) on nirsevimab
• Background on nirsevimab
• RSV Prevention
  • What is Respiratory Syncytial Virus 
  • RSV: When It’s More Than Just a Cold
  • CDC RSV Prevention